Fox Run Management, L.L.C. Reata Pharmaceuticals Inc Transaction History

Fox Run Management, L.L.C.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	BUY	$19.41 - $36.49 $200,932 - $377,744	10,352 New	10,352 $260,000
Q3 2020 Oct 29, 2020	SELL	$93.53 - $163.34 $135,805 - $237,169	-1,452 Closed	0 $0
Q2 2020 Jul 31, 2020	SELL	$126.3 - $176.56 $38,900 - $54,380	-308 Reduced 17.5%	1,452 $227,000
Q1 2020 May 08, 2020	BUY	$124.16 - $247.74 $62,949 - $125,604	507 Added 40.46%	1,760 $254,000
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $93,436 - $273,053	1,253 New	1,253 $256,000

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.